CLINICAL_TRIALS
trial_result
· 2014-12-18
Clinical Trial Update: A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma [Phase 1]
Summary
A Phase 1 safety study of SGN-40 (brentuximab vedotin) in patients with Non-Hodgkin lymphoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Seagen Inc. | Conditions: Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED